EP1720579A1

EP1720579A1 - Galactomannans and/or glucomannans for increasing the bioavailability of active substances

Info

Publication number: EP1720579A1
Application number: EP05715350A
Authority: EP
Inventors: Andreas Hefel
Original assignee: Wheli Inter AG
Current assignee: Wheli Inter AG
Priority date: 2004-02-17
Filing date: 2005-02-16
Publication date: 2006-11-15
Also published as: WO2005079857A1; JP2007524690A

Abstract

The invention relates to a method for increasing the bioavailability of nutrients by using polysaccharides such as galactomannans and similar for introducing active substances, e.g. the human growth hormone HGH and others, into the human or animal metabolism. The aim of the invention is to further develop the production of polysaccharides such as galactomannans and glucomannans in such a way that the same are also suitable for introducing active substances such as the human growth hormone into the human or animal metabolism.

Description

GALAKTOMANNANE AND / OR GLUCOMANNANE FOR INCREASING ACTIVE BIOLOGICAL AVAILABILITY

US 4,675,312 discloses the production of polysaccharide agglomerates with the aim of enabling better intake by avoiding the other problems of galactomannan flour, such as viscosity and stickiness. 0 The production is carried out here by two different substances, namely one by the galactomannan and the other Second, through separate agglomeration formers. 5 The agglomeration agent is hardly restricted in the choice of available substances. It is only defined as a water supplier and can be of animal and / or vegetable origin. The proportion of agglomeration agents in the total granulate is between 5 to 40%. Examples of such agglomeration formers are potatoes, milk and fruit. US Pat. No. 4,675,312 accordingly describes the production of granules from galactomannans and associated agglomeration formers.

The US patent only describes the use of these granules as dietary fiber.5 The finished mix was taken with liquid, which, together with the interstinal liquid, contributed to the swelling of the product. The health value was therefore only limited to the amount of dietary fiber.

However, this document does not disclose how to use such granules for the embedding of active substances. In particular, the introduction of the growth hormone HGH into the human or animal body was not evident. The HGH consists of a total of 188 amino acids and, as a long-chain peptide, is difficult to introduce into the human or animal body.

The invention is therefore based on the object of further developing the preparation of polysaccharides, such as galactomannans and glucomannans, specified in US Pat. No. 4,675,312 so that they are also suitable for introducing active substances, such as human growth hormone, into human or animal metabolism ,

To achieve the object, the invention is characterized by the technical teaching of claim 1.

The use of granules for oral ingestion by humans and animals is described. A novel absorption kinetics of water-soluble vital substances, such as HGH, is claimed. Delaying the penetration of water into the granules is an advantage with regard to the delayed release of water-soluble vital substances. Fat-soluble vital substances are administered in an oily suspension, making absorption independent of nutrition.

The invention describes the possibility of individual compilation of the granules described with their effect on the human organism.

The invention thus has the following features: • Use of plant ingredients • Carrier by polysaccharides • Application in various areas (anti-aging, competitive sports) The active ingredients are embedded individually or as a complex separately in a plant matrix (polysaccharides / guar). The advantage is the delayed , delayed release of the active substances into the blood, the exclusion of undesired interactions of different active substances with one another (antagonism) and the building up of large absorption surfaces in the small intestine. The production of monopreparations and complexes as semi-finished preparations makes it possible to produce completely individual vital substance preparations for humans and animals in the simplest way.

The combination of a “modular system” for the simple production of individual preparations and the special embedding of vital substances in plant polysaccha de (eg guar) is claimed, among other things, as essential to the invention.

In the table below, in addition to the active ingredient HGH specified under number 1, a number of other active ingredients are specified which are to be introduced into the human or animal body together with the HGH. Any active substance combination of substance 1 with all further substances 2 to 15 is thus claimed to be essential to the invention.

1. HGH - (somatotropin)

2. L-methionine in the body converts it to cysteine, which is itself assembled into gluthathione.

3. L-glutathione (GSH) antioxidant, antitoxin and enzyme cofactor. An anti-degenerative, systemic protectorant.

4. N-acetyl-L-cysteine (NAC) a more stable form of L-cysteine. NAC is the most effective way to increase glutathione levels in the body.

5. Arginine pyroglutamate triggers the secretion of growth hormones and increases the perception function.

6. Lycopene, caroten (corotenoids) the most effective antioxidant.

7. NADH (nicotinamide, adenine, is required for the regeneration of glutathione, dinucleotide) a coenzyme after it is oxidized. 8. Alpha lipoic acid (ALA) antioxidant, which counteracts the free radicals in the mitochondria, where the cell energy originates. Reduces the risk of macular degeneration.

9. Chromium Constituents of the glucose tolerance factor, which helps in reducing blood glucose levels.

10. Acetyl-L-carnitine (ALC) reduces brain cell death.

11. Ginseng extract

12. Green tea extract is well known and has documented anti-aging effects.

13. Guar from guar gum galactomannan, acts as a fiber and vegetable carrier matrix of the active ingredients. 14. Konjac from the Konjac plant glucomannan, acts as a fiber and carrier matrix of the active ingredients.

Table 1: The combination of the HGH with other active ingredients

In the following, substances that can be important for the metabolism are referred to as active substances or vital substances. Active ingredients can be vitamins, minerals, trace elements, plant ingredients, amino acids, coenzymes and other metabolically active substances in Table 1. However, the invention is not limited solely to the active substances given in Table 1.

The active ingredient is dissolved in water or, in the case of fat-soluble active ingredients, it is suspended in water. This solution or suspension is slowly introduced into the purified polysaccharide and mixed. The resulting gel is dried using a gentle process in order not to destroy the sometimes sensitive active ingredients with temperature or oxygen. The cake resulting from the drying is crushed and sieved to the desired particle size (preferably 0.2 - 2 mm). The granulate obtained in this way has a residual moisture of about 5 - 7% and is therefore microbiologically stable.

When the granulate is ingested, it begins to swell and the embedded active ingredients are slowly released for absorption by the human or animal digestive system. A gel forms. The high density of the polysaccharide matrix ensures that the swelling process only takes place in the interstinal tract. Water is continuously absorbed during the swelling process, thus loosening the matrix. In the course of this loosening, the embedded active ingredients can diffuse out of the matrix and thus be absorbed. The amount of active ingredient that is absorbed does not therefore exceed physiological concentrations, as can happen when a capsule or conventional dosage forms are released.

The continuous dissolution of the polysacccha gel through the digestive process causes the delayed release of the embedded active ingredients. This behavior largely corresponds to the natural conditions when taking vitamins or other active ingredients. Fruit, vegetables, meat, and cereals are colloidal systems, as is the hydrocolloid galactomannan or glucomannan.

This increases the bioavailability of the embedded active ingredients. By taking capsules, tablets or powder according to the state of the art up to now, the active ingredient reaches high concentrations in the blood quickly and unphysiologically and is therefore excreted again more quickly or partially not taken up at all. The incorporation described can delay the delivery of the active ingredient. The absorption kinetics that can be achieved by incorporating the active substance into the polysaccha d are shown in Figure 1. Example 1 :

Production of granules with active ingredient coenzyme Q10:

62 kg of guar gum are placed in a mixer, then a solution of 18 kg of coenzyme Q10 and 18 kg of D, L-alpha tocopherol acetate as an antioxidant in 15 kg of isopropyl alcohol is added. Mix and then add water until the product reaches maximum moisture. By adding water, the polysaccharide matrix begins to swell and the active substance coenzyme Q10 penetrates the polysaccharide chains and is thus immobilized. Subsequent drying under vacuum conditions removes the moisture from the product at room temperature to a residual moisture content of 5-7%, thus stabilizing the product. The cake formed during drying is broken and sieved to the required grain size of 0.2 to 2 mm.

Example 2:

Production of a vitamin C granulate:

Dissolve 10 kg of ascorbic acid in 50 l of water. 30 kg of guar gum and 30 kg of konjac flour are placed in a mixer and the ascorbic acid solution is added. During the mixing process, the moisture content is adjusted to the maximum achievable moisture level by adding more water. The mixed mass is frozen, crushed and then dried by lyophilization. The cake formed during drying is broken and sieved to the required grain size of 0.2 to 2 mm.

Example 3:

Production of a trace element granulate:

Preparation of a solution of 480 g of copper sulfate in 10 l of water, a second solution of 3.2 kg of zinc sulfate heptahydrate in 10 l of water and a third solution of 5 g of nathumselenite pentahydrate in 5 l of water. 22 kg of guar and 7 kg of potato starch are placed in a mixer and mixed. The individual solutions are then added and worked in one after the other. The maximum achievable humidity is set with water. Subsequent drying in a hot air stream removes moisture from the product to a residual moisture content of 5-7% withdrawn. The cake formed during drying is broken and sieved to the desired grain size of 0.2 to 2 mm.

The following features are therefore claimed to be essential to the invention:

• Retard effect of the built-in active ingredients • Prevention of undesired interactions between the active ingredients, both in the preparation and in the gastrointestinal tract • Natural release behavior of the carrier (water-soluble, indigestible polysaccha d), thereby improving the absorption properties • By building up a large absorption surface in the Small intestine improved absorption properties

The subject matter of the present invention results not only from the subject matter of the individual patent claims, but also from the combination of the individual patent claims with one another.

All of the information and features disclosed in the documents, including the summary, in particular the spatial configuration shown in the drawings, are claimed to be essential to the invention, insofar as they are new to the prior art, individually or in combination.

In the following, the invention will be explained in more detail with reference to drawings showing several possible embodiments. Further features and advantages of the invention which are essential to the invention emerge from the drawings and their description.

Show it:

Figure 1: Comparison of the kinetics of drug delivery in a conventional preparation compared to the drug when incorporated into a polysaccharide; FIG. 2: an enlarged, schematic representation of a granulate consisting of individual granulate particles;

FIG. 3: an enlarged and schematic representation of a granulate particle with incorporation of HGH complexes;

FIG. 4: a schematic illustration, which is enlarged still further compared to FIG. 3;

Figure 5: the functional kinetics of the molecular structure when water penetrates.

FIG. 1 shows a comparison of the active substance release in the human or animal body using two different active substance mechanisms.

The active substance concentration in the blood is shown on the ordinate, while the time is shown on the abscissa.

Curve Y shows a conventional transition of an active ingredient into the human or animal body. The result of this is that an approximately parabolic course is created, i. H. a very sharp increase in

Active ingredient concentration on the curve branch 12, which culminates already after an hour at the apex 13 and drops very quickly in the area of the descending curve branch 14.

It follows from this that the availability of the active ingredient is only available for a short time.

Furthermore, it follows from the steep curve branches 12, 14 and the high apex 13 lying in between that unphysiologically high active substance concentrations - sometimes in an undesirable manner - occur. This is where the invention comes in, which, with the flatter curve X, represents an active ingredient built into a polysacchahd and its transition into the blood of the human or animal body. The active substance concentration increases over a longer time in the region of the curve branch 15, there being only a weak apex 16, which proves that no undesirably high and unphysiological overdoses are to be feared. The drop in active ingredient in the region of the curve branch 17 is also only very small, so that the diagram in FIG. 1 shows that the relatively high active ingredient concentration at the apex 16 is maintained over a very long time.

The comparison of curve Y compared to curve X thus shows that, thanks to the technical measures according to the invention, a high concentration of active substance in the blood can be achieved over a long period of time.

The graphic shows the possibility of a desired absorption delay by embedding the active ingredient in a polysacchahd. This means a more uniform supply and better use of the active ingredients in human and / or animal metabolism.

FIG. 2 shows an example of a granulate 1 which consists of a large number of granulate particles 2, 3.

In one granulate z. B. ascorbic acid, as described in Example 2 above.

In the other granule particle 3, for example, the growth hormone HGH is embedded, as it is shown graphically as an HGH complex. This installation mechanism is mentioned in Example 3 of the above description.

It is important that the two granulate particles 2, 3 are completely functionally separated and do not mix or interact with one another in an undesirable manner. Because the active substances (ascorbic acid and selenite) are bound in different granulate particles 2, 3, an undesired interaction between these active substances in the gastrointestinal tract is prevented.

Details of the installation of an HGH complex 7 are explained in more detail with reference to FIGS. 3 to 5.

With an enlarged, electron-microscopic representation of a granulate particle 3, it can be seen that it is formed from a multiplicity of reticulated or lattice-shaped polysaccharide molecules 5, which form a lattice structure 4.

In the spaces 6 of this lattice structure 4, the HGH complexes 7 are now integrated into the lattice structure 4 of the polysaccharide molecules 5 by means of a coordinative bond.

It should also be mentioned that the polysaccharide molecules 5 themselves are each surrounded by an illustrated HO shell which completely envelops and shields the thread-like structure.

In the further enlarged representation according to FIG. 4 it can be seen that 5 OH groups are attached to the filiform polysaccharide molecules, which are part of the polysaccharide molecule 5.

The HGH complexes 7 are integrated in the space 6 between the molecules 5 due to the previously mentioned coordinative bond. The HGH complexes are multivalued positive, while the OH group 8 carries a negative partial charge.

In this way, the HGH complexes are kept in the space 6 between the filiform polysaccharide ions due to the described coordinative bond.

This is the reason for the delayed release, because when water enters the composite according to FIG. 4, the reaction kinetics according to FIG. 5 result. There, it can again be seen that the polysaccharide molecules 5 encased in a water shell are bound to one another in the interspace by water molecules, in the interspace of which the HGH complexes 7 are also present.

If water or intestinal fluid penetrates into the interspaces 6, the bond between the molecules 5 is partially broken and these shift two-dimensionally in the arrow directions 10, 11.

The bond between the polysaccharide molecules 5 is thus partially broken and the HGH complexes 7 are released into the surrounding liquid.

This is the reason for the delayed release because there is still partial adhesion and binding in the space 6 between the polysaccharide molecules 5. Furthermore, the delayed release is justified by the fact that the individual threads are removed in layers by the penetrating water or the interstinal fluid and thus the lattice structure is also removed in layers so as to release the HGH complexes 7 stored in the interspace 6.

In the following it will be described how it comes to the previously described hydration cover 9.

The galactomannan fibers are very closely connected in the dry flour. Mixing this network with water loosens these threads and surrounds them with the previously mentioned hydrate shell 9.

It is thus possible in an inventive manner to create the lattice structure of the polysaccharide molecules 5 in such a way that they are surrounded by the hydrate shell (H ₂ O shell 9) mentioned. This hydrate shell provides the intermediate bond between the individual polysaccharide molecules 5, as was shown on the basis of the reaction kinetics in FIG.

drawing Legend

granules

Granules (Asc)

Granules (Se)

lattice structure

Polysacchahd molecule

gap

HGH complex

OH group

H ₂ O envelope

arrow

curve branch

vertex

curve branch

vertex

curve branch

Claims

claims

1. A method of increasing nutrient bioavailability in a subject who desires such an increase which involves administration of a nutritionally effective amount of at least one nutritional supplement and a bioavailability-increasing amount of galactomannan and / or glucomannan.

2. The method according to claim 1, characterized in that HGH (origin somatotropin) is embedded in galactomannans and / or glucomannans.

3. The method according to claims 1 and / or 2, characterized in that said nutritional material includes at least one material selected from a group consisting of herbal extracts, water-soluble vitamins, fat-dissolving vitamins, amino acids, fatty acids, minerals and anti-oxidants and Hormones.

4. The method according to any one of the preceding claims, characterized in that said herbal extracts have been selected from a group consisting of Ashwaganda, Boswellin, Capsaicin, Curcumin, milk thistle extract, Sceletium and Ayurvedic herbal extracts.

5. The method according to any one of the preceding claims, characterized in that said water-soluble vitamins are selected from a group consisting of vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, folic acid, inositol, pantothenic acid and vitamin C, wherein the fat-soluble vitamins are selected from a group consisting of vitamin A, vitamin D, vitamin E and biotin.

6. The method according to any one of the preceding claims, characterized in that said water-soluble vitamins are selected from a group consisting of vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, folic acid, inositol, pantothenic acid and vitamin C can be selected, the fat-soluble vitamins being selected from a group consisting of vitamin A, vitamin D, vitamin E and biotin.

7. The method according to any one of the preceding claims, characterized in that said anti-oxidants are selected from a group consisting of mixed carotenoids, the co-enzyme Q10, lycopene, lutein, zeaxanthin, bioflavonoids, germanium, selenium, zinc, vitamin A, vitamin C and vitamin E, alpha lipoic acid, grape seed phytosome, green tea extract and pine bark extract.

8. The method according to any one of the preceding claims, characterized in that said amino acids are selected from a group consisting of N-acetyl-cysteine, acetyl-L-carnitine, L-arginine HCL, L-carnitine, endorphenil D-phenylaline, GABA, L-glutamine, L-glycine, L-histidine, L-lysine, L-methinine, L- and DL-phenylalaline, proline, taurine, 5-hydroxy-tryptophan, L-tyrosine.

9. The method according to any one of the preceding claims, characterized in that said minerals are selected from a group consisting of calcium, chromium, copper, germanium, iodine, iron, magnesium, manganese, calcium, selenium, silicon, vanadium, zinc ,

10. Use of polysaccharides, such as galactomannans, glucomannans and the like, for the introduction of active substances into human or animal metabolism, characterized in that the vital substances are embedded individually or as a complex separately and functionally separated from one another in a plant matrix of the polysaccharide.

11. Use of polysaccharides such as galactomannans, glucomannans and the like for introducing active substances according to one or more of claims 1 to 11, characterized in that the vital substances are embedded individually or as a complex separately and in each case functionally separated from one another in a plant matrix of the polysaccharide.

12. Use according to claim 11 or 12, characterized in that the vital substances are vitamins, minerals, trace elements, plant substances, amino acids, coenzymes and other metabolically active substances.

13. Use according to one of claims 11 to 13, characterized in that the active ingredient is dissolved in water or, in the case of fat-soluble active ingredients, this is suspended in water, the solution or suspension is slowly introduced and mixed into the purified polysaccharide, the resulting gel through a gentle process is dried, the cake formed by the drying is crushed and sieved to the desired particle size (preferably 0.2-2 mm).

14. Polysacchahd according to one of claims 11 to 14, characterized in that a granulate (1) consists of a multiplicity of granulate particles 2, 3, a first active ingredient is embedded in a first granulate particle and a second active ingredient is incorporated in a second granulate particle.

15. Polysacchahd according to claim 15, characterized in that the granulate particles (2, 3) are functionally separated, and do not interact with each other in an undesirable manner.

16. Polysacchahd according to one of claims 11 to 16, characterized in that the granulate particle (2, 3) is formed from a multiplicity of reticulated or lattice-shaped polysaccharide molecules 5 which form a lattice structure 4 and that in the interspaces (6) the lattice structure (4) the active substance ions (7) are integrated into the lattice structure (4) of the polysaccharide molecules (5) by means of a coordinative bond.

17. Polysacchahd according to one of claims 11 to 17, characterized in that the polysaccharide molecules (5) are surrounded by an H ₂ O shell which completely envelops and shields the thread-like structure.

18. Polysacchahd according to one of claims 11 to 18, characterized in that OH groups are attached to the filiform polysaccharide molecules (5) and that in the space (6) between the molecules (5) the active substance ions 7 with a coordinative Are involved.

19. Polysacchahd according to one of claims 11 to 19, characterized in that when water or intestinal fluid penetrates into the interstices (6) of the molecules (5), they move two-dimensionally against one another (in the arrow directions 10, 11).

20. Polysacchahd according to one of claims 11 to 20, characterized in that the delayed release of the active substances takes place in that the individual threads are removed in layers by the penetrating water or the intestinal fluid and thus the layer structure is also removed in layers, so that the im Intermediate space (6) releasing active substance ions (7).

21. Polysacchahd according to one of claims 11 to 21, characterized in that the thread-like molecules are surrounded by a hydrate coat (H ₂ θ shell 9).